Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: FLU Clear all
Withdrawn Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

NCT01224795
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo Comparator
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
96
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age

NCT02290509
View directory record Official record
Conditions
Influenza
Interventions
Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4)
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Sacramento, California • Coral Gables, Florida • Savannah, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Jul 23, 2026, 4:07 PM EDT
Completed No phase listed Observational

Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults

NCT01000571
View directory record Official record
Conditions
H1N1 Pandemic Flu
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Months to 21 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 6, 2011 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 1 Interventional

An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...

NCT01086657
View directory record Official record
Conditions
Influenza A Virus, H5N1 Subtype
Interventions
VRC-AVIDNA036-00-VP, Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Results available

A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants

NCT00412737
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Year and older
Enrollment
477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
34
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Stanford, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2016 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza

NCT02287467
View directory record Official record
Conditions
Influenza A, Influenza B
Interventions
Intravenous hyperimmune immunoglobulin (IVIG), Placebo for IVIG
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
San Diego, California • Denver, Colorado • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults

NCT00973349
View directory record Official record
Conditions
Influenza
Interventions
MF59-eH1N1_f
Biological
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
2,719 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
20
States / cities
Miami, Florida • Lenexa, Kansas • Omaha, Nebraska + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2015 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Not applicable Interventional Results available

The Respiratory Protection Effectiveness Clinical Trial

NCT01249625
View directory record Official record
Conditions
Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus, Rhinovirus
Interventions
N95 Respirator, Medical/surgical mask
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
2,862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
7
States / cities
Aurora, Colorado • Denver, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infectivity of Norovirus in Groundwater-Human Challenge Study

NCT00313404
View directory record Official record
Conditions
Healthy
Interventions
Safety tested norovirus inoculum
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Sanofi H1N1 + TIV - Adults and Elderly

NCT00943878
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine, Inactivated H1N1 Vaccine, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
805 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

NCT02814643
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Mesa, Arizona • Huntington Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children

NCT01091246
View directory record Official record
Conditions
Healthy or Stable Chronic Illness
Interventions
Q/LAIV (MEDI3250), FluMist/B/Yamagata, FluMist/B/Victoria
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
2 Years to 17 Years
Enrollment
2,312 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
110
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Jul 23, 2026, 4:07 PM EDT
Withdrawn Phase 1 Interventional

A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

NCT05600582
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
CodaLytic
Biological
Lead sponsor
Codagenix, Inc
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

NCT06602024
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years and older
Enrollment
40,817 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
188
States / cities
Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 150 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

NCT00521586
View directory record Official record
Conditions
Influenza
Interventions
13 valent pneumococcal conjugate vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 59 Years
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
41
States / cities
Chandler, Arizona • Rolling Hills Estates, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies

NCT00617110
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
live attenuated influenza virus (LAIV) with clean air, LAIV and diesel exhaust particles
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Jul 23, 2026, 4:07 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention

NCT02015494
View directory record Official record
Conditions
Influenza
Interventions
VAX2012Q
Biological
Lead sponsor
VaxInnate Corporation
Industry
Eligibility
18 Years to 40 Years
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
Lenexa, Kansas • Rochester, New York • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Results available

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

NCT01808456
View directory record Official record
Conditions
Influenza, Human, Transplantation Infection
Interventions
influenza trivalent inactive vaccine, influenza trivalent inactive vaccine high dose
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 70 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children

NCT00344305
View directory record Official record
Conditions
Healthy
Interventions
Trivalent influenza virus vaccine live, intranasal
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
6 Months to 59 Months
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
16
States / cities
Little Rock, Arkansas • Marietta, Georgia • Bardstown, Kentucky + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2017 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Not applicable Interventional Results available

Patient Portal Flu Vaccine Reminders (5)

NCT05525494
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Text Fixed R/R Messages with Direct Appointment Schedule Link, Text Pre-Appointment Reminder, Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link, Portal Fixed R/R Messages with Direct Appointment Schedule Link, Portal Pre-Appointment Reminder
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months and older
Enrollment
262,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

NCT06020118
View directory record Official record
Conditions
Influenza, COVID-19
Interventions
Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Years to 64 Years
Enrollment
455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
8
States / cities
Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations

NCT01746082
View directory record Official record
Conditions
Influenza
Interventions
Influenza A/H3N2 variant Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
4
States / cities
Decatur, Georgia • Iowa City, Iowa • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VRC 309: A Multi-Center, Open-Label, Randomized Phase I Study of an Investigational Influenza DNA Vaccine Followed by 2009/2010 Seasonal Influenza Trivalent Inactivated Vaccine (TIV) Compared to Two Injections of TIV in Adults 45-70 Years

NCT00995982
View directory record Official record
Conditions
Influenza, Human
Interventions
VRC-FLUDNA056-00VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
45 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland • Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 4:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

NCT01498718
View directory record Official record
Conditions
Influenza
Interventions
DNA vaccine, TIV
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Decatur, Georgia • St Louis, Missouri • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Jul 23, 2026, 4:07 PM EDT